AstraZeneca plc isn’t the only high-growth stock I’d buy today

This stock could deliver high returns alongside AstraZeneca plc (LON: AZN).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Stating that AstraZeneca (LSE: AZN) is a high-growth stock may sound rather unusual. After all, the company has delivered a number of years of declining profitability as its patent cliff has come to the fore. The loss of patents on many of its key, blockbuster drugs has caused its pre-tax profit to decline from $7.7bn in 2012 to just $3.6bn in 2016.

Clearly, it has been a challenging period for the business. However, following major investment in its pipeline, the company’s outlook looks set to improve. This could make it a strong growth play for the long run, but it’s not the only stock that could offer impressive returns. Reporting on Tuesday was another healthcare industry company which could be worth buying today.

Improving performance

The company in question is specialist biodecontamination products provider Bioquell (LSE: BQE). It delivered a positive trading update which showed that revenue for the full year will be ahead of its previous expectations. It is expected to be around £29.3m, which is a significant improvement on the prior year’s figure of £26.8m.

Should you invest £1,000 in AstraZeneca right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if AstraZeneca made the list?

See the 6 stocks

Within that figure of £29.3m, around £28.6m is from the biodecontamination business. This represents a growth rate of 13% versus the previous year. The remaining £0.7m is from the defence business, where revenues fluctuate significantly from year to year.

Pre-exceptional earnings are due to be significantly ahead of market expectations. This could be a key reason why the stock price of Bioquell increased by around 12% following its update. With the company expected to report a further rise in its bottom line of 10% in the current year. This could help to stimulate investor sentiment towards the company and allow it to post further gains following its share price rise of 130% in the last year.

High total returns

Of course, Bioquell lacks the diversity, size and scale of AstraZeneca. Therefore, the larger of the two healthcare companies could offer a stronger overall risk/reward ratio. With the stock trading on a price-to-earnings (P/E) ratio of 18, it seems to offer a fair price for the long term. It also has a dividend yield of 4.1%, with shareholder payouts being covered 1.4 times by profit. This suggests that they are highly sustainable at their current level and could rise at a relatively fast pace over the long run.

While AstraZeneca may not be a particularly popular stock at the present time, a changing outlook for stock markets could make it a more in-demand company to own. With investors currently focused on cyclical growth stocks, defensive companies which do not have high positive correlation with the rest of the economy are relatively unpopular. This could therefore provide an opportunity for investors to buy them at low prices and achieve relatively high total returns.

With the healthcare sector being highly defensive and offering a high degree of diversity, both AstraZeneca and Bioquell could be worth buying for the long term.

Should you buy AstraZeneca shares today?

Before you decide, please take a moment to review this first.

Because my colleague Mark Rogers – The Motley Fool UK’s Director of Investing – has released this special report.

It’s called ‘5 Stocks for Trying to Build Wealth After 50’.

And it’s yours, free.

Of course, the decade ahead looks hazardous. What with inflation recently hitting 40-year highs, a ‘cost of living crisis’ and threat of a new Cold War, knowing where to invest has never been trickier.

And yet, despite the UK stock market recently hitting a new all-time high, Mark and his team think many shares still trade at a substantial discount, offering savvy investors plenty of potential opportunities to strike.

That’s why now could be an ideal time to secure this valuable investment research.

Mark’s ‘Foolish’ analysts have scoured the markets low and high.

This special report reveals 5 of his favourite long-term ‘Buys’.

Please, don’t make any big decisions before seeing them.

Claim your free copy now

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter Stephens owns shares in AstraZeneca and Bioquell. The Motley Fool UK has recommended AstraZeneca. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Woman riding her old fashioned bicycle along the Beach Esplanade at Aberdeen, Scotland.
Investing Articles

This beaten-down FTSE 250 stock trades at a 10-year low and yields a stunning 12%!

Harvey Jones is staggered by the astonishing yield on offer from this FTSE 250 stock. It's a mind-boggling rate of…

Read more »

Silhouette of a bull standing on top of a landscape with the sun setting behind it
Investing Articles

3 beaten-down shares to consider buying before the next bull market

Instead of waiting for stocks to start moving higher, Stephen Wright thinks investors should look for shares that might be…

Read more »

Black father and two young daughters dancing at home
Investing Articles

UK investors piled into these S&P 500 stocks during the Liberation Day sell-off…

Our writer wasn't surprised to see AJ Bell investors buying into the S&P 500 earlier this month, though one popular…

Read more »

UK coloured flags waving above large crowd on a stadium sport match.
Investing Articles

A stunning 10% dividend-yield stock to consider for a Stocks and Shares ISA!

Harvey Jones says Stocks and Shares ISA investors should consider FTSE 250 fund manager aberdeen, a recovery stock that pays…

Read more »

UK financial background: share prices and stock graph overlaid on an image of the Union Jack
Investing Articles

Here’s why the AstraZeneca share price dipped 3.7% in the FTSE 100 today

Despite AstraZeneca’s falling share price today, this writer believes the London-listed pharmaceutical giant could be worth a closer look.

Read more »

Photo of a man going through financial problems
Investing Articles

I asked ChatGPT to name 3 growth stocks to consider buying in today’s dip. Here they are!

Harvey Jones wants to use the stock market sell-off to buy some great value growth stocks and decided to call…

Read more »

Serious thinking young woman
Investing Articles

Are Associated British Food shares now one of the FTSE 100’s greatest bargains?

Associated British Food (ABF) shares have slumped on news of tough retail conditions. Is the FTSE 100 stock now too…

Read more »

Businessman hand stacking up arrow on wooden block cubes
Growth Shares

Putting £450 in the stock market each month could be worth this much in a decade

Jon Smith explains which sectors could offer high growth potential for the coming decade and how to make the stock…

Read more »